AU2001296854A1 - Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity - Google Patents

Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity

Info

Publication number
AU2001296854A1
AU2001296854A1 AU2001296854A AU9685401A AU2001296854A1 AU 2001296854 A1 AU2001296854 A1 AU 2001296854A1 AU 2001296854 A AU2001296854 A AU 2001296854A AU 9685401 A AU9685401 A AU 9685401A AU 2001296854 A1 AU2001296854 A1 AU 2001296854A1
Authority
AU
Australia
Prior art keywords
hadh2
erab
modulating
inhibiting
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296854A
Other languages
English (en)
Inventor
Melwyn A Abreo
Charles Scott Agree
Jerry J. Meng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Publication of AU2001296854A1 publication Critical patent/AU2001296854A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001296854A 2000-08-18 2001-08-17 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity Abandoned AU2001296854A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22612300P 2000-08-18 2000-08-18
US60226123 2000-08-18
PCT/US2001/041795 WO2002016365A1 (fr) 2000-08-18 2001-08-17 Composés de pyrazole, compositions pharmaceutiques, et procédés de modulation ou d'inhibition de l'activité erab ou hadh2

Publications (1)

Publication Number Publication Date
AU2001296854A1 true AU2001296854A1 (en) 2002-03-04

Family

ID=22847647

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296854A Abandoned AU2001296854A1 (en) 2000-08-18 2001-08-17 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity

Country Status (14)

Country Link
US (2) US6964957B2 (fr)
EP (2) EP1311511A1 (fr)
JP (2) JP2004506737A (fr)
AR (1) AR035486A1 (fr)
AU (1) AU2001296854A1 (fr)
BR (1) BR0113461A (fr)
CA (2) CA2415182A1 (fr)
GT (1) GT200100169A (fr)
HK (1) HK1046288A1 (fr)
MX (1) MXPA03001455A (fr)
PA (1) PA8525801A1 (fr)
PE (1) PE20020394A1 (fr)
UY (1) UY26895A1 (fr)
WO (1) WO2002016365A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10221052A1 (de) * 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
EP1627323A4 (fr) * 2003-05-06 2008-04-09 New Century Pharmaceuticals Sites de fixation sur l'albumine pour l'evaluation d'interactions medicamenteuses ou la mise au point de medicaments en fonction de leur proprietes de liaison a l'albumine
CA2585115A1 (fr) * 2003-11-03 2005-05-12 New Century Pharmaceuticals, Inc. Sites de liaison a l'albumine permettant d'evaluer des interactions medicamenteuses et procedes d'evaluation ou de conception de medicaments fondes sur les proprietes de liaison a l'albumine de ces derniers
WO2005117538A2 (fr) 2004-04-12 2005-12-15 The Trustees Of Columbia University In The City Of New York Procedes et compositions pour inhiber l'interaction entre l'enzyme abad et la proteine a$g(b)
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
AU2005289808B2 (en) * 2004-09-24 2011-11-03 The Government Of The United States As Represented By The Secretary Of The Army, U.S. Army Medical Research Institute Of Chemical Defense Method of treating organophosphorous poisoning
WO2010118367A2 (fr) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Pyrimidines antivirales
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
WO2023146880A1 (fr) * 2022-01-25 2023-08-03 Board Of Regents Of The University Of Nebraska Dérivés d'allopurinol fonctionnalisés pour le traitement de la maladie d'alzheimer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3165520A (en) 1965-01-12 Certificate of correction
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5322933A (en) * 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
US5294611A (en) 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5556778A (en) * 1994-04-28 1996-09-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Crystalline Inha Enzyme-NADH Complex
PL181895B1 (pl) 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6153652A (en) 1996-11-22 2000-11-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6268479B1 (en) * 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
AU731838B2 (en) 1997-03-14 2001-04-05 Otsuka Pharmaceutical Co., Ltd. Novel pyrimidine derivative
SK285991B6 (sk) 1997-04-25 2008-01-07 Pfizer Inc. Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
US6020162A (en) * 1997-06-13 2000-02-01 The Rockefeller University Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof
US5872011A (en) * 1997-06-13 1999-02-16 The Rockefeller University Crystal of a protein-ligand complex containing an N-terminal truncated eIF4E, and methods of use thereof
AU747705C (en) 1997-12-13 2004-09-23 Bristol-Myers Squibb Company Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
GB9822238D0 (en) 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
AU5311800A (en) 1999-06-10 2001-01-02 Warner-Lambert Company Rhodanine derivatives for use in a method of inhibiting amyloid protein aggregation and imaging amyloid deposits
WO2000076988A1 (fr) 1999-06-10 2000-12-21 Warner-Lambert Company Derives de la rhodanine et leur utilisation pour l'inhibition et la mise en images d'amyloides
SK17622001A3 (sk) 1999-06-10 2003-06-03 Warner-Lambert Company Izoindolínové deriváty, ich použitie a farmaceutické kompozície na ich báze
WO2001012598A2 (fr) 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Procedes d'inhibition de la liaison de la fibrille a feuillets beta au recepteur rage, et leurs consequences

Also Published As

Publication number Publication date
PA8525801A1 (es) 2002-08-29
WO2002016365A1 (fr) 2002-02-28
EP1223176A2 (fr) 2002-07-17
EP1223176A3 (fr) 2002-10-23
US20020132319A1 (en) 2002-09-19
EP1311511A1 (fr) 2003-05-21
AR035486A1 (es) 2004-06-02
US6964957B2 (en) 2005-11-15
MXPA03001455A (es) 2004-05-04
CA2415182A1 (fr) 2002-02-28
JP2004506737A (ja) 2004-03-04
BR0113461A (pt) 2003-07-01
US20020065292A1 (en) 2002-05-30
HK1046288A1 (zh) 2003-01-03
CA2354653A1 (fr) 2002-02-18
UY26895A1 (es) 2002-04-26
PE20020394A1 (es) 2002-06-21
GT200100169A (es) 2002-05-16
JP2002360269A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
AU781269C (en) Pharmaceutical compositions
ZA200203040B (en) Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation.
ZA200110022B (en) Thiazoloderivatives and pharmaceutical compositions containing them.
HUP0200355A2 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0202490A3 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU5326100A (en) Pharmaceutical compositions and methods for use
AU2002328494A1 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
AU2002364342A1 (en) Heteroxylan film-forming composition for making capsules and resulting capsules
AU2001281171A1 (en) Medication dispensing system
AU2001284149A1 (en) Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
AU2001296854A1 (en) Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity
AU2001292864A1 (en) Methods and compositions for modulating angiogenesis
EP1138643A3 (fr) Liant pour compositions hydrauliques et compositions hydrauliques le contenant
ZA200110150B (en) Streptogramin derivatives, preparation and compositions containing them.
AU2001292331A2 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2001292331A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2001273919A1 (en) Pharmaceutical compositions
AU7937500A (en) Pharmaceutical composition containing midazolam
AU2001284167A1 (en) Sprinkler system
AU2002360117A1 (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
AU2002210632A1 (en) Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same
AU2362701A (en) Fragrance or flavor formulation
HK1052168A1 (en) N-deacetylthiocolchincine derivatives and pharmaceutical compositions containing them.